Meta-Analysis:
The value of long noncoding RNA PANDAR as a biomarker of prognosis in carcinomas: a metaanalysis
Metrics: PDF 402 views | Full Text 580 views
Xin Yan1, Yanting Zhu1, Fangwei Li1, Wenhua Shi1, Jian Wang1, Qingting Wang1, Qianqian Zhang1, Limin Chai1 and Manxiang Li1
1Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China
Correspondence to:
Manxiang Li, email: [email protected]
Keywords: PANDAR; cancer; biomarker; prognosis; meta-analysis
Received: July 15, 2017 Accepted: December 04, 2017 Published: January 02, 2018
ABSTRACT
Promoter of CDKN1A antisense DNA damage activated RNA (PANDAR) has been demonstrated to be aberrantly expressed in various types of cancer and might be serve as a potential biomarker for human cancers. The present study conducted a meta-analysis to investigate whether the expression of lncRNA PANDAR was associated with prognosis and clinicopathological features in relevant cancers. 10 eligible studies with a total of 1211 patients were collected by searching the electronic bibliographic databases, the results show that high expression level of PANDAR could significantly predict shorter OS in cancer patients (HR = 2.08, 95% CI: 1.55-2.80, P < 0.001) except in patients with non-small cell lung cancer (NSCLC). There was also a significant association between high level of PANDAR and advanced TNM stage (OR = 2.80, 95% CI = 1.57-4.99, P < 0.001), positive lymph node metastasis (OR = 2.92, 95% CI = 1.92-4.45, P < 0.001), larger tumor size (OR = 1.41, 95% CI = 1.04-1.89, P = 0.03) and poor tumor differentiation (OR = 1.53, 95% CI = 1.09–2.15, P = 0.01). In conclusion, the meta-analysis results indicate that increased expression level of PANDAR was associated with unfavorable prognosis and might serve as a predictive factor for advanced clinicopathological features in various cancers.